Phase 3 MagnetisMM-32 Trial Results: Elrexfio (Elranatamab) Monotherapy Shows Statistically Significant PFS Benefit vs Three Standard Regimens in Relapsed/Refractory Myeloma (https://www.myeloma.org/news-events/multiple-myeloma-news/phase-3-magnetismm-32-results-elranatamab)